RhumbLine Advisers’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-87,810
| Closed | -$3.59M | – | 4394 |
|
|
2024
Q2 | $3.59M | Sell |
87,810
-15,380
| -15% | -$629K | ﹤0.01% | 1577 |
|
|
2024
Q1 | $4.36M | Buy |
103,190
+8,893
| +9% | +$376K | ﹤0.01% | 1484 |
|
|
2023
Q4 | $4M | Buy |
94,297
+6,626
| +8% | +$281K | ﹤0.01% | 1552 |
|
|
2023
Q3 | $1.91M | Sell |
87,671
-597
| -0.7% | -$13K | ﹤0.01% | 1882 |
|
|
2023
Q2 | $2.81M | Buy |
88,268
+4,546
| +5% | +$145K | ﹤0.01% | 1721 |
|
|
2023
Q1 | $2.04M | Buy |
83,722
+3,960
| +5% | +$96.6K | ﹤0.01% | 1797 |
|
|
2022
Q4 | $2.52M | Buy |
79,762
+10,118
| +15% | +$319K | ﹤0.01% | 1661 |
|
|
2022
Q3 | $1.97M | Buy |
69,644
+7,277
| +12% | +$206K | ﹤0.01% | 1770 |
|
|
2022
Q2 | $1.65M | Buy |
62,367
+21,322
| +52% | +$564K | ﹤0.01% | 1874 |
|
|
2022
Q1 | $1.44M | Buy |
41,045
+4,312
| +12% | +$151K | ﹤0.01% | 1972 |
|
|
2021
Q4 | $1.19M | Sell |
36,733
-51
| -0.1% | -$1.65K | ﹤0.01% | 2137 |
|
|
2021
Q3 | $1.09M | Buy |
36,784
+8,540
| +30% | +$252K | ﹤0.01% | 2196 |
|
|
2021
Q2 | $724K | Buy |
+28,244
| New | +$724K | ﹤0.01% | 2392 |
|